Moderna Files for Updated COVID-19 Vaccine Authorization
Moderna, Inc. announced the completion of its regulatory application to the FDA for its updated COVID-19 vaccine containing spike proteins for the XBB.1.5 sublineage of SARS-CoV-2. Moderna is introducing additional applications to regulators around the globe and is prepared to deliver updated COVID-19 vaccines in time for the fall vaccination season. Read more.

Immune Thrombocytopenia Low After mRNA-Based COVID-19 Vaccines
Previous research employing data from the CDC revealed that autoimmune hematologic diseases are rare after immunization for COVID-19, with rates appearing to be lower than those in the general population. However, there have been no studies that have directly compared the occurrence of de novo immune thrombocytopenia after receipt of COVID-19 vaccinations with de novo immune thrombocytopenia occurrence after other vaccines or COVID-19. Read more.

Global Regulatory Submissions for Moderna’s RSV Vaccine Announced
Moderna recently provided an update on regulatory submissions for mRNA-1345, a vaccine for the prevention of respiratory syncytial virus (RSV)–associated lower respiratory tract disease and acute respiratory disease in adults aged 60 years or older. The regulatory applications are established on positive data from a prespecified interim analysis of a pivotal study. Learn more about the results of this study.